PIN39 IMMUNIZATION BARRIERS AND SUGGESTED SOLUTIONS IN IRAQ  by Al-lela, O.Q.B. et al.
eligible persons aged 2-59 years of age. The study objectives were to determine the
cost-effectiveness of LAIV compared to TIV in Canadian children and adolescents
from aMinistry of Health (MoH) perspective and a societal perspective.METHODS:
A previously published US cost-effectiveness model using patient-level data to
compare LAIV and TIV was supplemented by secondary (e.g. literature) and pri-
mary data (i.e. survey of 144 Canadian physicians). To compare the costs and ben-
efits of LAIV and TIV, a cost-utility analysis was conducted. Parameter uncertainty
was addressed through probability sensitivity analysis (PSA). RESULTS: Although
LAIV increased vaccination costs compared to TIV, LAIV reduced the number of
influenza illness cases and lowered the number of hospitalizations, ER visits, out-
patient visits andparents’ days lost fromwork. The estimated offsets in direct costs
savedwere $4.19 per vaccinated child aged 2-17 years. Societal savings were $35.33
per vaccinated child. When costs and outcomes were considered, LAIV was the
dominant strategy when compared to TIV. At a willingness to pay of $50,000 per
QALY gained, the results of the PSA indicated that the probability of LAIV being
cost-effective was almost 1. CONCLUSIONS: LAIV reduces the burden of influenza
in children and adolescents. Consistent with US results, vaccinating children with
LAIV instead of TIV is the dominant strategy from a societal and MoH perspective.
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OBJECTIVES: To estimate the long-term costs and effectiveness of entecavir com-
pared with lamivudine and adefovir in treating chronic HBeAg-positive infection.
METHODS:We compare key outcomes related to survival, costs, and QOL for HBV
patients. A lifetime Markov model was used to estimate the expected outcomes
and costs for HBV patients treated with entecavir vs lamivudine and adefovir. The
impact of treatingHBVwith entecavir, lamivudine and adefovir in patientswho are
positive for hepatitis B e antigen (HBeAg) was based on the efficacy and safety
results of the Phase 3, double-blind, randomized controlled trial. Utility values
were derived from published literature. The cost-effective analysis was conducted
from the Mexican Healthcare perspective. Costs were derived from the literature
and expert interviews, future costs and effects were discounted at 5% per recom-
mendations for analyses in Mexico. All costs are presented in 2010 US dollars.
Multiple 1-way sensitivity analyses were performed to address uncertainty.
RESULTS: The model projects an accumulated discounted cost to the Mexican
healthcare systemper patient receiving the entecavir regimen of $28,356 compared
to $28,325 for adefovir and $27,901 for lamivudine regimen. The base-case analysis
presented incremental cost-effectiveness ratios for entecavir vs adefovir and lami-
vudine of $123 per QALY and $ 1,574 per QALY respectively. These values are in
accordance with the recommendations of the Commission on Macroeconomics
and Health, WHO, suggesting that health technologies with ICERs below the per
capita GDP are considered very cost-effective. Results were robust to various as-
sumptions tested in the sensitivity analysis. CONCLUSIONS: Results from this
study analyses suggest that in the Mexican setting, use of entecavir in place of
adefovir and lamivudine for treatment of HBV is likely to be cost effective. These
conclusions are supported by conservative assumptions and sensitivity analysis.
Infection – Patient-Reported Outcomes & Preference-Based Studies
PIN36
ANTIRETROVIRAL REFILL ADHERENCE IN COMMUNITY HIV SPECIALTY
PHARMACIES (HIV-SP) VERSUS NON-SPECIALIZED PHARMACIES (NSP)
Cocohoba J1, Murphy P2, Pietrandoni G2, Guglielmo J1
1University of California San Francisco School of Pharmacy, San Francisco, CA, USA, 2Walgreens
Pharmacy, Deerfield, IL, USA
OBJECTIVES: Community pharmacies focused on HIV offer enhanced services to
assist patients taking antiretrovirals (ARV), yet the impact of these services is un-
clear. The objective of this study was to determine differences in patient charac-
teristics, regimen characteristics, and regimen refill adherence for HIV-SP versus
NSP users. METHODS: We conducted a retrospective database study of patients
with ARV claims fromMay 2007 – August 2009 at CaliforniaWalgreens pharmacies.
A modified medication possession ratio (mMPR) was used to calculate regimen
refill adherence. Patients were deemed “regimen adherent” on any given study day
if they possessed three or more antiretroviral drugs that included: a protease in-
hibitor, a non-nucleoside reverse transcriptase inhibitor, raltegravir, an entry in-
hibitor, abacavir, or tenofovir. A patient’s regimen adherent days were summed,
then divided by the total number of study days contributed to calculate themMPR.
A multivariable logistic regression model was constructed to determine indepen-
dent factors which contributed to having  95% regimen refill adherence.
RESULTS: 4254 HIV-SP and 11679NSP userswere included. Compared to NSP users,
HIV-SP users traveled farther to their pharmacies (5.03 vs. 1.26 miles), filled more
chronic disease medications (35% vs. 30%) and psychotropics (42% vs. 39%), and
received more fixed dose combination (FDC) ARVs (92% vs. 83%;); all p  0.01.
Median regimenmMPRwas higher for HIV-SP users (90% vs. 77%, p 0.0001). After
adjustment for various factors, both the use of HIV-SP (OR 1.79, 95% CI 1.72-2.08)
and fixed dose combination ARV tablets (OR3.3, 95% CI 2.86-4.01) were associated
with a greater likelihood of having95% regimen refill adherence. CONCLUSIONS:
Patients filling their prescriptions at HIV-SP are more likely to use fixed dose com-
bination ARV and have higher regimen refill adherence; particularly those taking
FDCs. HIV-SP should be further explored to determine whether specific services
improve patient adherence.
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OBJECTIVES: Immunization dosewas considered as amissed immunization dose if
pediatric didn’t receive at least one immunization dose. The aims of this study are
to determine the frequency and percent of missed doses among pediatric immu-
nization schedule, to determine the number of immunization doses missed by
each child, and to evaluate the correlation between missed dose frequency and
parent’s knowledge.METHODS: Data was collected retrospectively from 528 pedi-
atric immunization cards in Iraq to obtain the immunization history of each indi-
vidual child. This study was restricted the analyses to the vaccines administered
before age of 2 years. Each pediatric must received seven doses at seven different
times, every dose consist of many types of vaccines. Validated questionnaire was
used to measure immunization parent’s knowledge and Spearman rho correlation
test was used to evaluate the correlation between missed dose frequency and
parent’s knowledge. RESULTS:More than 30% ofmissed immunization doses were
shown in the seventh or last dose (OPVDTP) at 18 months of age. The majority of
pediatrics (54.1%) was immunized without any missed immunization dose out of
seven immunization doses. Four pediatrics (0.8%) were only having six missed
immunization doses. Missed immunization dose found to be negatively correlated
with knowledge score (correlation 0.263, P-value0.001). CONCLUSIONS: This
study suggests that compliancewithWHO immunization recommendations is low
and inappropriate immunization doses were occurred frequently, and leading to
incomplete or partial immunization compliance. With an increase in parent’s
knowledge of immunization guidelines against infectious agents, it is very impor-
tant to implement strategies that will lead to improved and developed immuniza-
tion practice and childhood immunization coverage in the future.
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OBJECTIVES: Immunization dosewas considered as a right immunization dose if it
was administered at the recommended age. The aims of this study are to deter-
mine the frequency and percent of this type of doses among pediatric immuniza-
tion schedule, to determine the number of right immunization dose received by
each child, and to evaluate the correlation between right dose frequency and par-
ent’s knowledge.METHODS: Data was collected retrospectively from 528 pediatric
immunization cards in Iraq to obtain the immunization history of each individual
child. This study was restricted the analyses to the vaccines administered before
age 2 years. Each pediatric must received seven doses at seven times, every dose
consist of many types of vaccines. Validated questionnaire was used to measure
immunization parent’s knowledge and Spearman rho correlation test was used to
evaluate the correlation between right doses frequency and parent’s knowledge.
RESULTS:More than 45% of right immunization doses were shown in the first dose
(BCGOPVHEP B.) at first week of pediatric life. The majority of pediatric (28%)
were immunized with one right immunization dose out of seven immunization
doses. Four pediatric (0.8%) were only immunized with seven normal immuniza-
tion doses, while 132 pediatric (25%) were immunized without any dose as right
immunization dose. Right immunization dose found to be positively correlated
with knowledge score (correlation 0.358, P-value0.001). CONCLUSIONS: This
study found that compliance with WHO immunization recommendations is low
and inappropriate immunization doses were occur frequently, and leading to in-
complete or partial immunization compliance.With an increase in parent’s knowl-
edge of immunization guidelines against infectious agents, it is very important to
implement strategies that will lead to improved and developed immunization
practice and childhood immunization coverage in the future.
PIN39
IMMUNIZATION BARRIERS AND SUGGESTED SOLUTIONS IN IRAQ
Al-lela OQB1, Bahari MB1, Alabbassi MG2, Basher AY1
1Universiti Sains Malaysia (USM), Pinang, Malaysia, 2Almustansaria Universiti, Baghdad, Iraq
OBJECTIVES: Vaccine barriers addressed in this study were included lack of edu-
cation, lack of funding, lack of vaccine availability, lack of medical facilities, and
fear of a side effect. The aims of this study are to determine immunization barriers
and to evaluate the solutions suggested by parents. METHODS: A cross sectional
prospective surveywas carried out among 528 Iraqis parentswith child had improper
immunization schedule to obtaineddemographic data of immunized children. Trans-
lated and validated questionnaire were administered to parents, it consisted of mul-
tiple choice questions. The questions were related to the immunization barriers and
how to decrease this barrier? RESULTS:More than 90% of pediatrics have improper
immunization schedule with immunization doses errors. The majority of parents
perceived that the lack of vaccine availabilitywas themost common immunization
barrier (51.5%), and more than 42% of parents perceived that the lack of education
was the important barrier, while 88.4% of parents were thought that the lack of
founding wasn’t important immunization barrier. More than 60% of parents sug-
gested increasing immunization programs in the media to promote pediatrics im-
munization, and 44.7% of parents suggested increasing mother’s education to pro-
mote immunization. But 77.5% of parents thought that any increase in fundingwill
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not benefit pediatric immunization. CONCLUSIONS: This is the first of this kind of
study in Iraq. The study recommended to increase the vaccine availability in public
health clinics and to increase in the father and mother’s education through media
program or through increasing the literacy. The family income or immunization
funding weren’t important because of the immunization in Iraq is free and sup-
ported by world health organization (WHO).
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OBJECTIVES: To quantify patient and physician preferences for therapeutic
tradeoffs involving efficacy, side-effect risks, and evidence uncertainty in chronic
hepatitis B (CHB) treatments. METHODS: Physicians who treat CHB patients and
adult patients with a self-reported physician diagnosis of CHB completed a web-
enabled, discrete-choice experiment survey in Germany and Turkey. Both patients
and physicians answered 12 treatment-choice questions. Each question required
evaluating a pair of hypothetical CHB medication profiles defined by years the
medicine has been studied, probability that patient’s viral load remains undetect-
able for 5 years with possible reversal of disease progression, 5-year treatment-
related risks of a fracture and renal insufficiency, and monthly medication cost.
Nested-logit and random-parameters logit models were used to estimate prefer-
ence weights for all attribute levels and the mean relative importance of each
attribute. RESULTS: A total of 158 physicians and 118 patients completed the sur-
vey in Germany. 159 physicians and 117 patients completed the survey in Turkey.
German patients ranked risk of renal insufficiency as most important while Ger-
manphyscians ranked efficacy asmost important. Turkish physicians andpatients
disagreed on the relative importance of all treatment attributes. Turkish patients
ranked years of evidence as themost important attribute,while Turkish physicians
ranked risk of renal insufficiency as most important. German physicians were
willing to accept a 0.4% greater increase in fracture risk than patients in return for
an additional year of evidence, while Turkish physicians were willing to accept a
3.2% smaller increase in fracture risk than patients for an additional year of
evidence. CONCLUSIONS: This is the first study to quantify patient and physician
preferences for CHB treatment attributes and the first study to elicit physician and
patient preferences for years of evidence. We observe different discrepancies be-
tween physician and patient preferences in Germany and Turkey. Such discrepan-
cies may interfere with optimal outcomes if not considered in patient-physician
interactions.
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OBJECTIVES: Given increasing concerns about a global influenza pandemic, the
aim of the current study was to investigate influenza vaccination rates among
high-risk adults and the general U.S population. METHODS: Data from the 2007-
20010 U.S. National Health andWellness Surveys (NHWS) were used. Demograph-
ics, comorbidities, and vaccination behavior in the past year were assessed for all
respondents, in addition to health-related quality of life (SF-12v2) and resource use
(number of emergency room visits and hospitalizations) in the past six months.
RESULTS: Overall, vaccination rates in the U.S. have steadily increased in the past
several years (2007: 30.0%; 2008: 32.8%; 2009: 34.3%; 2010: 37.0%). In 2010, 54.1% of
respondents (n40,541) were at high risk for influenza complications (e.g., over age
50, had chronic conditions such as asthma, diabetes, COPD, cardiovascular condi-
tions, or HIV/AIDS). These high-risk respondents reported significantly lower levels
of physical component summary scores (Means45.3 vs. 52.0, p.0001) and more
ER visits (Means0.22 vs. 0.17, p.0001) and hospitalizations in the past sixmonths
(Means0.15 vs. 0.07, p.0001) than low-risk respondents. Vaccination rates were
significantly higher for these high-risk respondents (48.6% vs. 23.2%, p.0001). No
high-risk subgroup reported vaccination rates higher than 67% (respondents with
kidney disease and HIV/AIDS reported vaccination rates of 66.5% and 67.3%, re-
spectively). In fact, many high-risk subgroups reported vaccination rates substan-
tially below 50% (caregivers of high-risk patients, respondents with multiple scle-
rosis, and pregnant women reported vaccination rates of 43.6%, 37.1%, and 30.5%,
respectively). CONCLUSIONS: Even as new universal recommendations issued by
the CDC may have some beneficial impact, overall vaccination rates were well
below 50% for the general U.S. population, even among certain high-risk subgroups
(e.g., pregnant women, caregivers). Greater emphasis on influenza vaccination,
particularly among high-risk patients, may have a long-term health outcome ben-
efit.
Infection – Health Care Use & Policy Studies
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OBJECTIVES: The antifungal market demonstrated dynamic changes with in-
creased incidence of fungal infections, resistance to traditional medications, and
entry of novel and generic therapies, which may significantly impact Medicaid
budgets for outpatient populations. Our objectives were: To describe utilization
and spending trends and to analyze the market share of antifungal agents indi-
cated for invasive fungal infections (IFI), from 1991 to 2009. METHODS: The data
source used in the study was the National Medicaid State Drug Utilization data
from 1991 to 2009, with records on outpatient prescription claims. Antifungal
agents in the study included all brand and generic drug names. Medications were
identified using National Drug Codes. Quarterly number of prescriptions and reim-
bursement amount were calculated for the descriptive trends. Market share of
spending for each drug was quantified over time. The quarterly price per prescrip-
tion was calculated by dividing the total reimbursement by the total number of
prescriptions. RESULTS: After entry of fluconazole in 1993, prescription claims for
amphotericin reduced by 95% from 1991 to 1995, and continued decreasing with
entry of lipid preparations. Prescription claims for fluconazole rose until 2004, then
declined by 25% with entry of new triazoles and echinocandins. More recently,
second generation triazoles dominated market share by 70%. Price-per-prescrip-
tion of lipid preparations of amphotericin decreased by 55%, but increased by 50%
for voriconazole. The price-per-prescription of itraconazole continuously rose
from $150-400 from 1992 to 2009. CONCLUSIONS: Increased use of lipid prepara-
tions of amphotericin may be due to improvement in adverse event profiles, con-
sequently leading to decreased demand for original formulation of amphotericin.
The decreased use of brand and generic fluconazole may be due to resistant fungi
and emergence of novel agents with broad-spectrum of activity. Itraconazole has a
niche market which contributes to its increasing price. Cost-effective decisions
appear to drive the use of antifungal agents.
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OBJECTIVES: Pegylated interferon-alpha plus ribavirin [P/R] are the standard of
care [SOC] for treating hepatitis C [HCV]. Few studies have evaluated the economic
implications associated with P/R treatment in real world practice. This study’s
objective is to quantify the correlation between P/R treatment duration and health
care costs in real-world clinical practice.METHODS: Paid claims data for 2003-2008
from a large U.S. health insurance company were used to identify 1,074 HCV pa-
tients with a minimum of two years of data following the start of P/R drug therapy
[index date]. Patients with a pre-treatment diagnosis for HIV, hepatitis B, cirrhosis,
liver cancer or a liver transplantationwere excluded. Patientswith 24-48weeks and
48 weeks of continuous P/R therapy were compared to patients with  24 weeks
of therapy. The multivariate analyses estimated the incremental effects of 24-48
and 48 weeks of P/R therapy controlling for baseline demographics, diagnostic
profile, and prescription drug profile. RESULTS: An estimated 82% of HCV patients
were viral genotype 1 based on limited available lab data. Genotype 1 patients
require 48weeks of treatment. 55.6% and 18.5% of study patients complete 24-48
weeks or 48weeks of drug therapy, respectively. Drug costs associatedwith 24-48
weeks of treatment were$9,832 [p0.0001] whichwere partially offset by savings
in medical costs of -$1,446 [p0.05] in the first year. First year drug costs for pa-
tients with 48 weeks of treatment were $25,696 [p0.0001] which was partially
offset by medical costs savings of -$5,535 [p0.05]. However, in the second year,
24-48 weeks of treatment was associated with a combined reduction in both med-
ical and prescription drug costs totaling -$7,590 [p0.05]. Patients achieving 48
weeks of treatment experienced a reduction in total second-year costs of -$9,334
[p0.05]. CONCLUSIONS: A full course of P/R therapy may reduce total cost over
time.
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OBJECTIVES: Pakistan is one of the four countries around the world harboring
polio. Government of Pakistan is spending lot of resources to eradicated polio in the
form of EPI (Extended Program of Immunization) initiated in 1994. The aim of our
study is to determine whether this government funded polio control program has
any impact on knowledge, attitude and perception of polio in general community.
METHODS: A cross sectional study was conducted. 477 respondents aged between
25 to 60 yearswere selected bymultistage stratified systematic sampling. KAPwere
assessed through self administered questionnaire which was developed and vali-
dated before administering to respondents. Statistical analysis was done by SPSS
16.RESULTS: 225 (47%) respondentswere female and 252 (53%)weremale.Majority
of respondents (95.4%) have heard about polio and 96.9%were of opinion that every
child must be vaccinated against polio. 27.3% of respondents believed that it is
sufficient to vaccinate a child once in life against polio. 85.1% of subject were not
aware that whether it is communicable or non-communicable disease. 31.5% of
respondents showed confidence in the capability of polio vaccination team about
providing appropriate information. 48.3% of respondents were satisfied from the
awareness campaigns of the government propagated through mass media about
polio, its prevention and timing of vaccination. CONCLUSIONS: Government is
spending lot of money on EPI but appropriate knowledge, positive attitudes and
perceptionswere found in smaller proportion of participants. This study points out
that there is need to maximize education programs to make general public aware
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